Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin BP Reduction in Hypertension and T2DM
NCT01939496Phase 4Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Oct 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (3 arms), sponsored by Janssen Scientific Affairs. Primary endpoint: Change From Baseline in the Mean 24-Hour Systolic Blood Pressure at 6 weeks. Started Oct 2013; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT01939496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939496.